Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst

All NewsApril 8, 2026

Stifel initiates coverage on Summit Therapeutics (SMMT) with a Buy rating and $45 price target, citing ivonescimab’s $200B market potential.

Latest Ratings for SMMT

DateFirmActionFromTo Nov 2020HC Wainwright & Co.DowngradesBuyNeutral Mar 2020HC Wainwright & Co.Initiates Coverage OnBuy Jun 2018Janney Montgomery ScottDowngradesBuyNeutral

View More Analyst Ratings for SMMT

View the Latest Analyst Ratings

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent